6月12日,据CDE官网消息,乐普生物科技股份有限公司联合申请药品“MRG007”,获得临床试验默示许可,受理号CXSL2500262。公示信息显示,药品“MRG007”适应症:局部晚期或转移性实体瘤。乐普生物科技股份有限公司,成立于2018年,位于上海市,是一家以从事医药制造业为主的企业。企业注册资本165944.4838万人民币,实缴资本149269.2648万人民币。通过天眼查大数据分析,...
Source Link6月12日,据CDE官网消息,乐普生物科技股份有限公司联合申请药品“MRG007”,获得临床试验默示许可,受理号CXSL2500262。公示信息显示,药品“MRG007”适应症:局部晚期或转移性实体瘤。乐普生物科技股份有限公司,成立于2018年,位于上海市,是一家以从事医药制造业为主的企业。企业注册资本165944.4838万人民币,实缴资本149269.2648万人民币。通过天眼查大数据分析,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.